Regeneron Pharmaceuticals (BOVESPA:REGN34) - Hisse Senedi Fiyatı, Haberler ve Analizler

REGN34 Stoklara Genel Bakış

Regeneron Pharmaceuticals, Inc. dünya çapında çeşitli hastalıkların tedavisi için ilaçlar keşfetmekte, icat etmekte, geliştirmekte, üretmekte ve ticarileştirmektedir. Daha fazla detay

REGN34 temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	5/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 51.3% daha düşük bir oranda işlem görüyor

Kazançlar geçen yıl 16.6% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Son 3 ayda dalgalı hisse senedi fiyatı

Regeneron Pharmaceuticals, Inc. Rakipler

Blau Farmacêutica

BOVESPA:BLAU3

R$2.6b

CSL

ASX:CSL

AU$131.4b

Amgen

NasdaqGS:AMGN

US$150.5b

Biogen

NasdaqGS:BIIB

US$22.6b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Regeneron Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$75.60
52 Haftanın En Yüksek Seviyesi	US$111.72
52 Haftanın En Düşük Seviyesi	US$64.40
Beta	0.14
11 Aylık Değişim	-20.54%
3 Aylık Değişim	-31.55%
1 Yıllık Değişim	16.59%
33 Yıllık Değişim	25.40%
5 Yıllık Değişim	209.03%
Halka arzdan bu yana değişim	265.15%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	REGN34	BR Biotechs	BR Pazar
7D	-4.5%	-6.9%	0.1%
1Y	16.6%	8.0%	-1.6%

Getiri vs. Endüstri: REGN34 geçen yıl % 8 oranında getiri sağlayan BR Biotechs sektörünü aştı.

Getiri vs Piyasa: REGN34 geçen yıl % -1.6 oranında getiri sağlayan BR Piyasasını aştı.

Fiyat Oynaklığı

Is REGN34's price volatile compared to industry and market?
REGN34 volatility
REGN34 Average Weekly Movement	6.4%
Biotechs Industry Average Movement	9.0%
Market Average Movement	4.5%
10% most volatile stocks in BR Market	8.4%
10% least volatile stocks in BR Market	2.2%

İstikrarlı Hisse Senedi Fiyatı: REGN34 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: REGN34 'nin haftalık oynaklığı ( 6% ) geçen yıl boyunca sabit kaldı, ancak hala BR hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1988	14,165	Leonard Schleifer	www.regeneron.com

Regeneron Pharmaceuticals, Inc. dünya çapında çeşitli hastalıkların tedavisi için ilaçlar keşfeder, icat eder, geliştirir, üretir ve ticarileştirir. Şirketin ürünleri arasında yaşlılığa bağlı makula dejenerasyonu ve diyabetik makula ödemini tedavi etmek için EYLEA enjeksiyonu; miyopik koroidal neovaskülarizasyon; diyabetik retinopati; neovasküler glokom; ve prematüre retinopatisi bulunmaktadır. Ayrıca yetişkinlerde ve pediatride atopik dermatit ve astımı tedavi etmek için Dupixent enjeksiyonu; metastatik veya lokal olarak ilerlemiş kutanöz skuamöz hücreli karsinomu tedavi etmek için Libtayo enjeksiyonu; yetişkinlerde heterozigot ailesel hiperkolesterolemi veya klinik aterosklerotik kardiyovasküler hastalık için Praluent enjeksiyonu; covid-19 için REGEN-COV ve yetişkinlerde romatoid artrit tedavisi için Kevzara solüsyonu sunmaktadır.

Regeneron Pharmaceuticals, Inc. Temel Bilgiler Özeti

Regeneron Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
REGN34 temel i̇stati̇sti̇kler
Piyasa değeri	R$462.48b
Kazançlar(TTM)	R$26.87b
Gelir(TTM)	R$79.94b

17.2x

F/K Oranı

5.8x

P/S Oranı

REGN34 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
REGN34 gelir tablosu (TTM)
Gelir	US$13.85b
Gelir Maliyeti	US$6.82b
Brüt Kâr	US$7.03b
Diğer Giderler	US$2.37b
Kazançlar	US$4.65b

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	43.26
Brüt Marj	50.75%
Net Kâr Marjı	33.61%
Borç/Özkaynak Oranı	6.8%

REGN34 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

REGN34 Stoklara Genel Bakış

Ödüller

Risk Analizi

Regeneron Pharmaceuticals, Inc. Rakipler

BOVESPA:BLAU3

R$2.6b

ASX:CSL

AU$131.4b

NasdaqGS:AMGN

US$150.5b

NasdaqGS:BIIB

US$22.6b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Announces Clinical Data from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal Pivotal Pulsar Trial Investigating Eylea Hd (Aflibercept) Injection 8 Mg with 12-Week Dosing Regimens

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma for Priority Review

Regeneron Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Regeneron Pharmaceuticals, Inc. Temel Bilgiler Özeti

17.2x

5.8x

Kazanç ve Gelir